Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,696.00
(
-0.42%
)
Dow Jones
46,225.15
(
0.00%
)
Brent Oil
109.31
(
2.56%
)
Bitcoin
69,823.76
(
-1.99%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: sluicer post# 158201

Tuesday, 03/12/2013 6:23:15 PM

Tuesday, March 12, 2013 6:23:15 PM

Post# of 257257
AMRN—I have no strong opinion one way or the other on whether Vascepa will get NCE status (and that’s what I’ve said all along). The document you referenced doesn’t add anything probative to the discussion, IMO.

The reason you probably thought I was negative on NCE status is that I’ve said I don’t expect AMRN’s patents to stand up to Paragraph-IV challenges, which can come soon if NCE status is not granted. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now